Citations

Clear

6055 citation(s) found for "Wu, Peter".

Cardiovascular Complications of Anaplasmosis: A Case of Acute Pulmonary Embolism and Literature Review
Gavrancic, Aleksandar, Jacobson, Christian M., Rabasovic, Veljko , Sviggum, Erik, Stojsavljevic, Jelena, Tarragona, Nestor, Mattingly, Peter J. , Dumic, Igor , Tarragona, Nestor G , Dumic, Igor , Sviggum, Erik

Mayo Clinic

Infectious Disease Reports | June 24, 2026 | Volume: 18 | Issue: 3 | Pages: 62

10.3390/idr18030062 | PMID 42346069 Get It

Background: Anaplasmosis is an emerging tick-borne infection that typically presents as a non-specific febrile illness, with variable degrees of cytopenias and liver tests abnormalities. Severe complications remain atypical and uncommon. Case Report: We report a case of acute pulmonary embolism (PE) occurring during confirmed anaplasmosis in a 73-year-old male with no traditional thromboembolic risk factors. The patient presented with fever, constitutional symptoms, thrombocytopenia, leukopenia, and abnormal liver tests, raising suspicion for a tick-borne illness. Despite early clinical improvement on doxycycline, persistent tachycardia triggered further evaluation and uncovered an acute PE. Comprehensive workup at admission and repeated 14 months later excluded inherited and acquired thrombophilias, malignancies, autoimmune diseases, and alternative infectious etiologies. The patient was treated with doxycycline 100 mg orally twice daily for 10 days and anticoagulation with unfractionated heparin followed by 6 months of apixaban for a first episode of provoked PE. He attained complete clinical recovery without recurrence of thrombosis at the two-year follow-up. Discussion: Infectious diseases are increasingly recognized as contributors to thrombosis through inflammation-mediated hypercoagulability and endothelial dysfunction. Pulmonary involvement in anaplasmosis typically manifests as pneumonitis, pneumonia or acute respiratory distress syndrome, but thrombotic complications such as PE are exceedingly rare. This case highlights a rare but clinically significant vascular complication of anaplasmosis and underscores the importance of considering thromboembolic events in patients with persistent or unexplained tachycardia. Conclusions: As the incidence of anaplasmosis continues to rise, greater awareness of its potential cardiovascular manifestations is essential. Early recognition and prompt treatment with doxycycline remain critical, while further studies are needed to better define the thrombotic risk associated with this infection.
Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia
Olzinski, Molly, Downer, Joshua, Rajbanshi, Binita, Li, Jingyao, Loureiro, Joseph, Heuer, Hilary, Ljubenkov, Peter, Vandevrede, Lawren, Staffaroni, Adam, Lario‐Lago, Argentina, Leichter, Dana, Wolf, Amy, Wise, Amy, Sanderson-Cimino, Mark, Barragan, Eden, Spina, S, Grinberg, Lea T., Seeley, William W., Casaletto, Kaitlin B., Kramer, Joel, Ramos, Eilana, Geschwind, Daniel, Cook, Casey, Petrucelli, L, Forsberg, Leah K., Gendron, Tania, Boeve, Bradley F., Rademakers, Rosa, Rosen, Howard J., Saloner, Rowan, Boxer, Adam L., Rojas, Julio C., Abdullah, M. Samy, Apostolova, Liana, Appleby, Brian, Bayram, Ece, Hp, Botha, Bozoki, Andrea, Brushaber, Danielle, Clark, David, Considine, Ciaran M., Darby, R. Ryan, Day, Gregory S., Dickerson, Bradford C., Dickson, Dennis, Domoto-Reilly, Kimiko, Dwosh, Emily, Faber, Kelley M., Fields, Julie A. , Fong, Jamie C., Foroud, Tatiana, Galasko, Douglas R., Gavrilova, Ralitza, Ghoshal, Nupur , Goldman, Jill, Graff-Radford, Jonathan, Graff-Radford, Neill, Grant, Ian M., Cn, Hales, Honig, Lawrence S., Gd, Hsiung, Huey, Edward D, Irwin, David, Jones, David T., Kantarci, Kejal, Knopman, David, Kolander, Tyler , Kornak, J M, Kremers, W., Kwan, Justin , Lapid, Maria, Lee, Suzee, Litvan, Irene, Lucente, Diane, Mackenzie, Ian R., Masdeu, J C, Massimo, Lauren, McGinnis, Scott, McMillan, Corey T., Mendez, Mario F., Mester, Carly, Miyagawa, Toji , Molden, Joie, Onyike, Chiadi, Pantelyat, Alexander, Pascual, Belen, Paulson, Henry, Ramanan, Vijay, Rankin, Katherine P., Rascovsky, Katya, Rhoads, Kristoffer , Savica, Rodolfo, Snyder, Allison, Sullivan, A. Campbell, Syrjanen, Jeremy, Tartaglia, M, Taylor, Jack, Tipton, P E, WEINTRAUB, S, Wint, Dylan, Wong, Bonnie, Yokoyama, Jennifer, Paulson, Henry L. , Barmada, Sami J. , Paulson, Henry L , Barmada, Sami , Cobigo, Yann , Worringer, Kathleen A. , Heuer, Hilary W. , VandeVrede, Lawren , Staffaroni, Adam M. , Wolf, Amy , Wise, Amy B. , Sanderson‐Cimino, Mark , Barragan, Eden V. , Grinberg, Lea T. , Seeley, William W. , Casaletto, Kaitlin B. , Kramer, Joel, Ramos, Eliana Marisa , Geschwind, Daniel H. , Forsberg, Leah K. , Gendron, Tania F. , Boeve, Bradley F. , Perneel, Jolien , Rademakers, Rosa , Rosen, Howard J. , Saloner, Rowan , Boxer, Adam L. , Rojas, Julio C. , Appleby, Brian S. , Barmada, Sami, Bayram, Ece , Botha, Hugo, Bozoki, Andrea C , Brushaber, Danielle , Clark, David, Considine, Ciaran , Dickerson, Bradford Clark , Dickson, Dennis, Domoto‐Reilly, Kimiko , Dwosh, Emily , Foroud, Tatiana, Graff‐Radford, Jonathan , Graff-Radford, Neill, Hales, Chadwick M., Honig, Lawrence S. , Hsiung, Ging-Yuek R., Huey, Edward D. , Jones, David T., Kantarci, Kejal , Kornak, John , Kremers, Walter, Kwan, Justin, Léger, Gabriel C. , Litvan, Irene , Lucente, Diane , Mackenzie, Ian R. , Massimo, Lauren , McGinnis, Scott, McMillan, Corey T. , Mendez, Mario F. , Mester, Carly , Pascual, Belén , Ramanan, Vijay, Rankin, Katherine P. , Roberson, Erik D. , Savica, Rodolfo , Snyder, Allison , Sullivan, A. Campbell , Syrjanen, Jeremy A. , Taylor, Jack C. , Tipton, Philip W., Vandebergh, Marijne , Weıntraub, Sandra , Wint, Dylan

Mayo Clinic

JAMA Neurology | June 22, 2026 | Volume: 83 | Issue: 8 | Pages: 778

10.1001/jamaneurol.2026.1927 | PMID 42329632 Get It

Importance TMEM106B is a frontotemporal lobar degeneration (FTLD) genetic susceptibility factor, and TMEM106B protein aggregates are a feature of aging and neurodegeneration. Whether TMEM106B protein levels are associated with clinical features is unknown. Objective To investigate the clinical associations of cerebrospinal fluid (CSF) TMEM106B in FTLD. Design, Setting, and Participants This cross-sectional study was conducted in 2 independent frontotemporal dementia (FTD) cohorts (recruitment from April 2009 through July 2023, with analyses from January 2025 through April 2026), with a 2-year follow up. This multicenter clinical study integrated clinical, genetic, biomarker, and neuroimaging data. Individuals were recruited through the University of California, San Francisco (n = 3733), or ALLFTD (n = 2343). Participants with available CSF were included. A discovery cohort (n = 271) included participants with sporadic neuropathology-confirmed FTLD; presymptomatic or symptomatic carriers of pathogenic variants in C9orf72 , GRN , or MAPT ; or controls. An independent validation cohort (n = 383) included participants with clinically diagnosed sporadic FTD, Alzheimer disease (AD), and controls. Exposures CSF samples for TMEM106B quantification with aptamer proteomics (SomaScan version 3.0 [discovery cohort] and SomaScan version 4.1 [validation cohort]). Main Outcomes and Measures Parametric tests compared the primary outcome, CSF TMEM106B, by disease severity, TMEM106B rs1990622 genotype, sex, clinical syndrome, pathological diagnosis, and pathogenic variant and determined associations with brain volume. Results In the discovery (n = 271; 136 women [51%]; median [IQR] age, 59 [38-80] years) and validation (n = 383; 183 women [48%]; median [IQR] age, 64 [50-78] years) cohorts, lower CSF TMEM106B was associated with more severe disease (β, −0.15; 95% CI, −0.24 to −0.04; P = .003), lower frontotemporal brain volumes (β, 0.42; 95% CI, 0.24-0.61; P < .001), and faster clinical progression (β, −2.21; 95% CI, −3.70 to −0.72; P = .001). Associations of TMEM106B with clinical disease severity were independent of those with neurofilament light chain. TMEM106B levels were influenced by TMEM106B rs1990622 genotype, where individuals with the protective G/G genotype had lower levels than the risk A/A genotype. CSF TMEM106B levels did not differentiate between FTLD subtypes or between FTLD and AD. Conclusions and Relevance Per the results of this cross-sectional study, TMEM106B is detectable in CSF and levels reflect disease severity in sporadic and genetic FTLD and AD, but levels are also influenced by the TMEM106B rs1990622 genotype. CSF TMEM106B could support further studies to understand the mechanisms of disease and develop clinical tools in FTLD and other neurodegenerative diseases.
Real‐world, multi‐omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS)
Sauta, Elisabetta, Lanino, Luca, Bewersdorf, Jan P, Kewan, Tariq, Ali, Najla H. Al, Fenaux, Pierre, Platzbecker, Uwe, Santini, Valeria, Brunner, Andrew M., Kuykendall, Andrew T., Bennett, John M. , Buckstein, Rena, Bejar, Rafael, Carraway, Hetty E., DeZern, Amy E., Hasserjian, R., Loghavi, Sanam, Odenike, Olatoyosi, Padron, Eric , Patnaik, Mrinal M., Stahl, Maximilian, Sekeres, M., Steensma, David P., Savona, Michael R., Taylor, Justin, Xu, Mina L., Sallman, David A., Nimer, Stephen D. , Hourigan, Christopher S., Wei, Andrew H., Riva, Elena , Ventura, Denise, Pinocchio, Nicole, Buizza, Alessandro , Russo, Antonio, D'Amico, Saverio, Delleani, Mattia , Travaglino, Erica , Tentori, Cristina A., Ferrari, Ivan, Crespi, Alessandra, Figini, Giulia , Matteo, Maria Di, Milanesi, Chiara, Castellani, Gastone, Borate, Uma M., Gore, Steven D., Kim, Tae K., Loosdrecht, Arjan A. van de , Daver, N., Wang, Sa A. , Foucar, Kathryn, Iastrebner, Marcelo, Miyazaki, Yasushi, Al‐Kali, Aref, Mittelmann, Moshe, Cluzeau, Thomas , Ades, Lionel, Germing, Ulrich, Garcia‐Manero, Guillermo, Kordasti, Shahram, Haferlach, Torsten, Zeidan, Amer M., consortia, An international study on behalf of GenoMed4all, Synthema, and icMDS, Zeidan, Amer M. , Buizza, Alessandro , Ficara, Francesca , Efficace, Fabio , Diez-Campelo, Maria , Orfao, Alberto , Wang, Sa A , Cluzeau, Thomas , Komrokji, Rami S , Della Porta, Matteo Giovanni , Zeidan, Amer M , Maggioni, Giulia , Todisco, Gabriele , Sauta, Elisabetta , Lanino, Luca , Ball, Somedeb , Bewersdorf, Jan Philipp , Fenaux, Pierre , Platzbecker, Uwe , Santini, Valeria , Xie, Zhuoer , Brunner, Andrew M. , Kuykendall, Andrew , Buckstein, Rena , Bejar, Rafael , Carraway, Hetty E. , Dezern, Amy Elizabeth , Griffiths, Elizabeth A. , Halene, Stephanie , Hasserjian, Robert P. , List, Alan F. , Loghavi, Sanam , Odenike, Olatoyosi , Patnaik, Mrinal M. , Roboz, Gail J. , Sekeres, Mikkael A. , Steensma, David P. , Savona, Michael R. , Sallman, David A. , Hourigan, Christopher S. , Wei, Andrew H. , Campagna, Alessia , Ubezio, Marta , Ventura, Denise , Pinocchio, Nicole , Zampini, Matteo , Russo, Antonio , Pesce, Francesco , D'Amico, Saverio , Asti, Gianluca , Tentori, Cristina Astrid , Ferrari, Ivan , Matteo, Maria Di, Brindisi, Matteo , Manes, Nicla , Crisafulli, Laura , Ficara, Francesca , Castellani, Gastone , Borate, Uma , Efficace, Fabio , Gore, Steven D. , Díez‐Campelo, María , Rozman, Marı́a , Órfão, Alberto , Foucar, Kathryn , Iastrebner, Marcelo , Scheinberg, Phillip , Miyazaki, Yasushi , Madanat, Yazan F. , Al‐Kali, Aref , Mittelman, Moshe , Adès, Lionel , Germing, Ulrich , Garcia‐Manero, Guillermo , Kordasti, Shahram , Haferlach, Torsten , Komrokji, Rami S.

Mayo Clinic

HemaSphere | June 22, 2026 | Volume: 10 | Issue: 6 | Pages: No page available

10.1002/hem3.70406 | PMID 42339339 Get It

Abstract Myelodysplastic syndromes (MDS) are clinically and biologically diverse disorders, emphasizing the need for personalized treatment approaches. The International Working Group for Prognostication of MDS (IWG_PM) recently introduced a molecular classification, referred to as the MDS taxonomy, that categorizes patients into 16 subgroups based on 21 gene mutations, 6 cytogenetic abnormalities, and loss of heterozygosity (LOH) at TP53 and TET2 loci. This study sought to validate and enhance the clinical relevance of the MDS taxonomy by analyzing a large retrospective cohort ( n = 5136) and transcriptomic data from a prospective cohort ( n = 477). The taxonomy successfully identified subgroups with distinct clinical characteristics and disease progression patterns. However, incorporating gene interactions from taxonomy subgroups did not improve the prognostic performance of the Molecular International Prognostic Scoring System (IPSS‐M). We further assessed whether the taxonomy could guide management in patients receiving disease‐modifying therapies. Except for the “ TP53 ‐complex” subgroup, taxonomy classifications were not predictive of hypomethylating agent response or transplant outcomes. Nonetheless, they correlated with overall survival, suggesting that while both IPSS‐M and the taxonomy capture disease biology, other non‐genetic factors may influence treatment response. RNA sequencing confirmed the biological distinctiveness of the taxonomy groups. Transcriptomic profiling of CD34+ bone marrow cells revealed unique, homogeneous gene expression patterns, particularly within the AML‐like, bi TET2 , SF3B1 , and TP53 ‐complex subgroups. Further integration of multi‐omics data may refine MDS classification, improving clinical decision‐making and guiding the development of targeted therapies.
Microtubule Acetylation Regulates the Malignant Phenotype of Glioblastoma and is a Promising Therapeutic Target
Dovas, Athanassios, Bhattacharya, Santanu, Kulkarni, Tanmay, Amini, Misha, Haddock, Ashley, Nagaiah, Naveen KH, Mukhopadhyay, Debrabrata, Suarez-Meade, Paola, Quinones-Hinojosa, Alfredo, Canoll, Peter, Kenchappa, Rajappa, Rosenfeld, Steven S. , Rosenfeld, Steven S , Zarco, Natanael , Bhattacharya, Santanu , Kulkarni, Tanmay, Liu, Yi , Haddock, Ashley , Nagaiah, Naveen K H, Suárez-Meade, Paola , Quiñones‐Hinojosa, Alfredo , Miller, Courtney A. , Kamenecka, Theodore M. , Canoll, Peter, Kenchappa, Rajappa S.

Mayo Clinic

No container title available | June 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.15.732342 Get It

ABSTRACT Glioblastoma (GBM) is universally lethal despite decades of research to find effective treatments. This highlights the need to identify druggable targets essential for sustaining the malignant phenotype but dispensable for normal tissue. We propose that the enzyme α-tubulin acetyl transferase ( ATAT1 ) meets these criteria. ATAT1 acetylates α-tubulin at lysine 40, which increases microtubule stability and promotes microtubule-based transport. While ATAT1 knockout mice have only a very mild phenotype, ATAT1 suppression in GBM has multiple therapeutic effects by reducing tumor invasion, proliferation, and therapeutic resistance. These translate not only into improved survival with ATAT1 targeting by itself, but also into synergy when ATAT1 deletion is combined with FDA approved therapies. This study strongly supports our conclusion that ATAT1 is a promising therapeutic target in GBM.
Menin regulates oncogenic cell identity transcriptional networks in multiple myeloma
Kumar, Subhasree , Franich, Rheana, Khong, Tiffany, Neville, Daniel, The, James, Rumler, Brandon, Alex, Shania, Dobbs, Grace, Lewis, Alexander C. , Hawkins, Edwin, Chesi, Marta, Spencer, Andrew, Gilan, Omer , Kats, Lev M. , Gruber, Emily , Franich, Rheana L. , Khong, Tiffany T. , Ang, Ching‐Seng , Rumler, Bradon, Howitt, George , Hawkins, Edwin, Bergsagel, P. Leif , Chesi, Marta , Spencer, Andrew

Mayo Clinic

No container title available | June 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.17.733047 Get It

Abstract Multiple myeloma (MM) is a heterogenous cancer that remains mostly incurable. A unifying feature of MM cells is a highly interconnected network of transcription factors and co-factors that coordinate the activity of super-enhancers to enforce myeloma cell identity. Targeting this network offers a promising avenue for therapeutic intervention across genetically diverse myeloma sub-types. Using integrated molecular and functional genomic approaches we identified Menin as a key driver of oncogenic gene expression in MM cells. Menin and its co-factor KMT2A bind at super-enhancers and maintain expression of essential myeloma genes, including IRF4. We demonstrate that Menin inhibitors, which have recently been approved for treatment of acute myeloid leukaemia, are highly active in myeloma cell lines and in vivo models. Combining Menin inhibitors with other super-enhancer targeting therapies such EP300/CREBBP inhibitors or immunomodulatory drugs (IMiDs) overcomes epigenetic plasticity in cells resistant to single agent treatment.
Evaluation Frameworks for Predictive and Generative Oncology AI: Current Standards, Cancer-Specific Gaps, and a Path Toward Clinical Use
Yost, Connor D., Callas, Bradley, Halligan, Peter, Palumbo, Peter, Rawal, Samarth, Leyfman, Yan , Yost, Connor , Leyfman, Yan , Yost, Connor , Halligan, Peter, Rawal, Samarth, Nguyen, Ryan H.

Mayo Clinic

Cancers | June 18, 2026 | Volume: 18 | Issue: 12 | Pages: 1981

10.3390/cancers18121981 | PMID 42352515 Get It

Artificial intelligence (AI) is now applied across oncology, including imaging, pathology, therapy selection, toxicity assessment, and survival modeling, and large language models (LLMs) have been adopted particularly quickly. Reported physician use of AI roughly doubled between 2023 and 2026. The frameworks used to evaluate these tools have not advanced at the same rate. Many are available, but each was designed for a single stage of the AI lifecycle, and none directly answers the question most relevant to a treating clinician: whether a given tool is appropriate for the individual patient under care. We reviewed the frameworks in current use, including TRIPOD+AI, PROBAST+AI, CLAIM, SPIRIT-AI, CONSORT-AI, DECIDE-AI, MINIMAR, and CREMLS, together with the oncology-specific ESMO EBAI and the newer LLM-specific guidance (TRIPOD-LLM, MI-CLEAR-LLM, CHART, and ESMO ELCAP). Each addresses part of the evaluation problem, but none is sufficient on its own for oncology, where the standard of care changes rapidly, assays drift, biomarker-defined subgroups are small, and a model validated in one period may perform poorly in the next. LLMs introduce additional challenges, including sensitivity to prompting, undisclosed vendor updates, behavioral drift, and hallucination rates approaching 50% on clinical quality-assurance tasks. The predictive-model frameworks were not designed to capture these failure modes. The central argument of this review is that the frameworks the field requires already exist; what is missing is their mandatory adoption. We propose that journals and regulators move from recommending these frameworks to requiring their use, and we outline a cancer-aware evaluation pathway together with the specific responsibilities of authors, reviewers, journals, and regulators in implementing it.
Correcting spatial transcriptomics data affected by a prevalent transcript leakage problem across platforms, species, and tissues
Shi, Christina Huan , Zhai, Yibo, Chow, Savio Ho-Chit , Flores, Jesus, Kern, Colin , Adams, Peter D, Ren, Bing, Zhu, Quan, Carver, Chase M., Yip, Kevin Y , Carver, Chase Matthew , Teneche, Marcos G. , Ren, Bing , Schafer, Marissa , Wei, Yingying , Yip, Kevin Y.

Mayo Clinic

No container title available | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.13.732076 | PMID 42367830 Get It

Abstract Spatial transcriptomics has been widely applied to study the spatial distribution of cell types, cell states, and specific gene expression in tissue samples. However, we show that there is a prevalent transcript leakage problem in spatial transcriptomics data, where transcripts expressed by a cell diffuse to its neighborhood and are recurrently detected in the nearby cells. By analyzing published data sets, we show that this problem is general across data produced from different tissues and different species using different imaging-based and sequencing-based spatial transcriptomics platforms. It affects both upstream tasks such as expression quantification as well as downstream tasks such as cell-type annotation and detection of spatially-dependent gene expression. To tackle the transcript leakage problem, we propose a reference-free Bayesian model-based method, DeLeakage, which cleans up the data much more effectively than existing denoising methods. DeLeakage also improves cell-type annotation and avoids false detection of spatially dependent expression.
Learning Curves and Complexity Evolution in Robotic Liver Surgery
Kuemmerli, Christoph , Hess, Gabriel Fridolin , Billeter, Adrian T. , Benedetto, Fabrizio Di , Odorizzi, Roberta, Sucandy, Iswanto , Aegerter, Noa L. E., Berchtold, Caroline , Bernardi, L. , Cristaudi, Alessandra , Balzano, E , Koh, Ye-Xin, Lin, Charles Chung-Wei, Fukumori, Daisuke , Tschuor, Christoph , White, Steve, Kroge, P Von, Heumann, Asmus , Meyere, Céline De, D’hondt, M, Haak, Fabian, Stättner, Stefan, Primavesi, Florian, Morgül, Haluk , Andreou, A, Ratti, F, Esquer, Ignacio Sánchez, Robles-Campos, Ricardo, Lopez-Lopez, Victor, Wakabayashi, Go , Nebbia, Martina, Rahbari, Nuh N., Ferretti, Stefano, Ettore, Giuseppe , Croner, RS , Dong, Y, Starlinger, P, Nickel, F, Müller, Beat P., Hess, Gabriel F , Guidetti, Cristiano , di Benedetto, Fabrizio , Sucandy, Iswanto , Aegerter, Noa L E , Berchtold, Caroline , Bernardi, Lorenzo , Cristaudi, Alessandra , Balzano, Emanuele , Ghinolfi, Davide , Goh, Brian K P , Fukumori, Daisuke , Tschuor, Christoph , Pandanaboyana, Sanjay , De Meyere, Celine , Seehofer, Daniel , Esquer, Ignacio Sánchez , Müller, Philip C , Koh, Ye-Xin , Lin, Charles Chung-Wei, Tschuor, Christoph , Kroge, Philipp H. von , D’Hondt, Mathieu , Haak, Fabian , Stättner, Stefan , Primavesi, Florian , Ratti, Francesca , Robles-Campos, Ricardo, López‐López, Víctor , Wakabayashi, Taiga , Nebbia, Martina , Gilg, Stefan , Birgin, Emrullah , Ferretti, Stefano , Ettore, Giuseppe Maria, Rahimli, Mirhasan , Nickel, Felix , Müller-Stich, Beat Peter

Mayo Clinic

Annals of Surgery | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000007123 | PMID 42307103 Get It

Objective: To evaluate the institutional learning curve of robotic liver resection (RLR), its association with surgical complexity and outcomes in an international multicenter cohort. Summary of Background Data: RLR is increasingly adopted worldwide, but the dynamics of the learning process and its impact on surgical outcomes remain poorly defined. Methods: This international, multicenter, retrospective cohort study included consecutive patients who underwent RLR between 06/2013 and 12/2024 across 22 expert centers. Based on the first 150 cases at each center, three phases were used to define the learning curve: operative time for competency, major complications for proficiency, and textbook outcome for mastery. Risk-adjusted generalized additive models were used to assess the learning process. Benchmark performance was compared to international reference values. Results: Among 2,331 patients, the most common indications were hepatocellular carcinoma (36%), benign lesions (23%) and colorectal liver metastases (21%). Operative time decreased after achieving competency (case #62), from 240 to 220 minutes ( P <0.001). Major morbidity reached a plateau during the proficiency phase (cases #63–138; 9% vs. 11%, P =0.144), while progression to mastery (cases #139–150) was associated with a higher rate of textbook outcome (76% vs. 87%, P =0.021). In contrast, conversion (5.1% vs. 4.9% vs. 2%), bile leak (4.0% vs. 5.3% vs. 3.8%), and 90-day mortality (0.7% vs. 0.9% vs. 0.9%) remained low and stable across all learning phases. Importantly, benchmark criteria for operative time, hospital stay, and textbook outcome were met across all complexity groups, including during the early learning phase. Conclusions: Robotic liver surgery shows progressive outcome improvement with early achievement of benchmark-level results and stable performance across increasing complexity. These findings indicate that, in experienced centers, RLR can be safely implemented and integrated into clinical practice, supporting its key role in modern hepatobiliary surgery.
GLUT9b- and ABCG2-mediated collecting duct urate transport uncovers a vasopressin-independent mechanism of renal water reabsorption
Hadla, Mohamad , Mardirossian, Jean Marc , Bichet, Daniel, Borghol, Abdul Hamid , Abboud, Georges, Ghanem, Ahmad , Chini, Eduardo N., Harris, Peter, Alper, Seth L., Vallon, Volker , Chini, Eduardo, Hadla, Mohamad , Vallon, Volker , Bichet, Daniel Georges , Abboud, Georges , Chini, Eduardo N. , Harris, Peter C. , Torres, Vicente E. , Alper, Seth L. , Chebib, Fouad T.

Mayo Clinic

Journal of Clinical Investigation | June 16, 2026 | Volume: 136 | Issue: 14 | Pages: No page available

10.1172/jci197021 | PMID 42298327 Get It

Renal water reabsorption is classically regulated by vasopressin V2 receptor (V2R) signaling through cyclic AMP and protein kinase A, driving apical accumulation of aquaporin-2 (AQP2). However, collecting duct water handling is also modulated by vasopressin-independent mechanisms. Here, we examined intracellular soluble urate as a vasopressin-independent regulator of AQP2 trafficking. Intracellular urate accumulation in collecting duct cells was mediated by enhanced apical urate uptake via GLUT9b and reduced apical urate efflux through ABCG2, triggering phosphodiesterase-4 activation, reduced cAMP, and downstream AMP-activated protein kinase (AMPK) activation. The resulting AQP2 accumulation at the apical membrane was independent of V2R signaling, required ongoing endocytosis, and was associated with features of postendocytic apical trafficking of internalized AQP2. In vivo ABCG2 inhibition with probenecid increased apical AQP2 abundance and markedly attenuated tolvaptan-induced polyuria in both wild-type and Pkd1 RC/RC autosomal dominant polycystic kidney disease (ADPKD) mice in a uricase-independent manner while preserving tolvaptan’s ADPKD-modifying efficacy. In a phase II trial with tolvaptan-treated patients with ADPKD, probenecid reduced urine volume and nocturia frequency. Together, these findings support a vasopressin-independent urate/AMPK/AQP2 pathway that regulates renal water handling and, in a preclinical ADPKD model, can uncouple cyst growth attenuation from the dose-limiting aquaretic effects of V2R antagonism.